Related Experiment Video

Updated: Mar 8, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.7K

Conservative pharmacotherapy vs. staged percutaneous coronary intervention for non-culprit vessels in patients with

Bo Zhao1, Jianjun Peng1, Lihui Ren1

  • 1Department of Cardiology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, P.R. China.

Experimental and Therapeutic Medicine
|January 21, 2017
PubMed

Insights

Staged percutaneous coronary intervention (SPCI) for non-culprit vessels in ST-segment elevation myocardial infarction (STEMI) patients led to better outcomes than conservative pharmacotherapy (CP). SPCI reduced major adverse cardiovascular events and recurrent myocardial infarction compared to CP.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Cardiovascular Medicine

Background:

  • ST-segment elevation myocardial infarction (STEMI) often involves multi-vessel disease requiring treatment decisions for non-culprit lesions.
  • Conservative pharmacotherapy (CP) and staged percutaneous coronary intervention (SPCI) are management options for these lesions.
  • Optimal strategy for non-culprit vessels post-STEMI PCI remains an area of active research.

Purpose of the Study:

  • To compare the clinical outcomes of conservative pharmacotherapy (CP) versus staged percutaneous coronary intervention (SPCI) in managing significant non-culprit vessels in STEMI patients.
  • To evaluate the rates of major adverse cardiovascular events (MACE), recurrent myocardial infarction, and recurrent angina pectoris.
  • To assess MACE-free survival rates between the two treatment strategies.

Main Methods:

  • A study involving 266 male and 40 female STEMI patients who underwent successful primary PCI.
  • Patients were divided into two groups: complete revascularization (CR) via SPCI of non-culprit vessels, and CP.
  • Follow-up data collected at 180 and 360 days to compare clinical endpoints.

Main Results:

  • The conservative pharmacotherapy (CP) group exhibited a significantly higher rate of major adverse cardiovascular events (MACE) at 360 days (12.7% vs. 6.1%, P=0.05).
  • Recurrent myocardial infarction rates were higher in the CP group (10.1% vs. 4.1%, P=0.04).
  • Recurrent angina pectoris was significantly more frequent in the CP group at both 180 (13.9% vs. 5.4%, P=0.012) and 360 days (18.4% vs. 8.1%, P=0.009).
  • MACE-free survival at 360 days was significantly better in the complete revascularization (CR) group (93.9% vs. 87.3%, P<0.05).

Conclusions:

  • Staged percutaneous coronary intervention (SPCI) of non-culprit vessels in STEMI patients is associated with superior clinical outcomes compared to conservative pharmacotherapy (CP).
  • Complete revascularization through SPCI demonstrates a significant reduction in MACE and recurrent ischemic events.
  • These findings support SPCI as a preferred strategy for managing significant non-culprit lesions in STEMI patients.

Keywords:
ST-segment elevation myocardial infarctionmajor adverse cardiovascular eventsnon-culprit lesionsstaged percutaneous coronary intervention

More Related Videos

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

24.9K
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

26.5K

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
357
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
361
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.3K
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
372
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
472
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
540